Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 open-label pediatric study of sotatercept in pulmonary arterial hypertension
MOH_2023-07-12_012293Phase 2Recruiting
- Sponsor
- Merck & Co.
- Start
- Jan 2023
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of sotatercept in pulmonary arterial hypertension (PAH) (4 cohorts), sponsored by Merck & Co. Primary endpoints: Safety and tolerability of sotatercept over 24 weeks and Pharmacokinetics of sotatercept over 24 weeks. Started Jan 2023; status: recruiting.
02
Drugs
sotatercept
03
Conditions
pulmonary arterial hypertension (PAH)
Beyond the preview
Go deeper on MOH_2023-07-12_012293.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2023-07-12_012293.